Topic: Abilify

Bristol-Myers sees big 4Q sales jump

EARNINGS MISS: Bristol-Myers Squibb Co. posts fourth-quarter adjusted earnings of $906 million, or 53 cents a share, on sales of $5.45 billion ...
Drugmaker Bristol-Myers Squibb Co. reported a 76 percent increase in the fourth-quarter profit Thursday, due to higher sales of eight drugs, lower ...

Antipsychotics

In schizophrenia, antipsychotic medications are proven effective in treating acute psychosis and reducing the risk of future psychotic episodes...

Alexza to explore strategic options

(Reuters) - Alexza Pharmaceuticals Inc said it will explore options including sale of assets, strategic business combination, or partnerships.The company has also given a 60-day notice of layoffs to all its employees to conserve cash to support operations.Alexza expects to significantly ...

Antipsychotic drugs tied to diabetes risk in kids

NEW YORK (Reuters Health) - The antipsychotic drugs that are increasingly being used to treat bipolar disorder, autism and other mental disorders in children may come with an increased risk of diabetes, a new study suggests.Previous research has linked the so-called second-generation ...

Advisers urge FDA to address antipsychotics in kids

GAITHERSBURG, Maryland (Reuters) - U.S. pediatric health advisers on Thursday urged drug regulators to continue studying weight gain and other side-effects of antipsychotic drugs as they are increasingly taken by children.The pediatric advisory committee voted 16-1 to support the U.S ...
Currently yielding a large 4.50% and trading at a reasonable 15 times earnings, Bristol Myers-Squibb (BMY) has been a good place for income...
This is one of a continuous series of articles that will highlight selected recent clinical trial updates for new drugs in the FDA approval...
If there has been any bad news lately for Bristol-Myers Squibb's (BMY) Yervoy, you would be hard-pressed to find it. Last week it got the all-clear...
Otsuka Pharmaceutical Co. Ltd. said a federal court ruled Monday that patents protecting the active ingredient behind the schizophrenia drug Abilify are valid and enforceable.. Otsuka discovered Abilify, which is approved for schizophrenia, bipolar disorder and depression. Shares of Bristol-Myers fell 24 ...